Intercollaborative Radiation Countermeasure (INTERACT) Consortium for Advanced Development of Medical Countermeasures to Mitigate/Treat Acute and Delayed Radiation Syndromes
相互协作辐射对策 (INTERACT) 联盟,促进减轻/治疗急性和迟发性辐射综合症的医疗对策高级发展
基本信息
- 批准号:10401455
- 负责人:
- 金额:$ 243.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-16 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAdolescentAdultAdvanced DevelopmentAgingAnimal ModelBiologicalBiological MarkersBiological ProcessBloodCell AgingClinicalClinical TrialsCommunicationCutaneousDataDevelopmentDoseDrug KineticsElderlyEnsureEventExposure toFailureFosteringFundingFunding OpportunitiesGenerationsGenomic InstabilityGoalsGovernment AgenciesHematopoieticHourInflammationInjuryInvestigationKnowledgeLaboratory ResearchLifeMarylandMedicalMedical centerMiniature SwineMissionMitochondriaModelingMolecularMorbidity - disease rateMultiple Organ FailureNational Institute of Allergy and Infectious DiseaseNuclearNuclear AccidentsOryctolagus cuniculusPharmaceutical PreparationsPharmacodynamicsPharmacologic SubstancePilot ProjectsPopulationProcessQuality of lifeRadiationRadiation AccidentsRadiation InjuriesRadiation SicknessesRadiation SyndromesRadiation ToxicityRadiation exposureRadiology SpecialtyReadinessRecording of previous eventsRecoveryRegulatory PathwayResearch PersonnelResource SharingResourcesSafetyServicesSiteTechnology TransferTestingTherapeutic InterventionTissuesTreatment EfficacyUnited States Food and Drug AdministrationUnited States National Institutes of HealthUniversitiesWhole-Body Irradiationanimal rulebasebody systemdata sharingdesigngastrointestinalimprovedindustry partnerinterdisciplinary approachinternational partnershipmedical countermeasuremedical schoolsmembermortalitymultidisciplinarymultiorgan injurynew therapeutic targetnonhuman primatepharmacometricspre-clinicalprogramspublic health emergencyradiation countermeasureresearch and developmentsynergismtissue regeneration
项目摘要
PROJECT SUMMARY/ABSTRACT - OVERALL
The Inter-collaborative Radiation Countermeasures (INTERACT) Consortium was assembled for the overall
goal of developing safe and effective medical countermeasures (MCM) to mitigate and/or treat the acute,
delayed, and long-term consequences of radiation exposure for all subsets of the civilian population in the event
of a radiological or nuclear (RadNuc) public health emergency. The biological complexity of multiorgan injury
(MOI) and failure associated with acute radiation sickness (ARS) and delayed effects of acute radiation exposure
(DEARE) requires a comprehensive, multidisciplinary approach to efficiently identify new targets for therapeutic
intervention and to move promising MCMs from the research laboratory to advanced pharmaceutical
development and approval under the U.S. Food and Drug Administration’s (FDA) Animal Rule (AR) regulatory
pathway. INTERACT, a newly formed University of Maryland School of Medicine (UMSOM)-based Center for
Medical Countermeasures against Radiation (CMCR), is a partnership of internationally-recognized investigators
from four U.S.-based universities who possess a broad depth of expertise in MCM development, a unique set of
animal model platforms, and a common goal of sharing ideas and quality practices to advance the cutting-edge
scientific discovery and translational development of MCMs.
INTERACT projects are broadly designed around a common theme to promote tissue regeneration through
targeting the biological processes involved in cellular degeneration that contribute to the clinical manifestation of
ARS/DEARE after prompt exposure to high-doses of total body irradiation (TBI). Candidate MCMs under
investigation target key biological mechanisms associated with a radiation-induced accelerated aging process
including genomic instability, mitochondrial damage, cellular senescence, and inflammation that leads to the
hematopoietic (Project 1) and gastrointestinal subsyndromes of ARS (Projects 2, 3), cutaneous radiation injury
(Project 3), and DEARE (Projects 1 and 4). Preliminary datum for each of the MCMs under investigation in
Projects 1-4 have shown a significant improvement in survival when administered at least 24 hours post-
exposure and strong safety profiles in preclinical, and in some cases clinical trials. To advance MCM
development within the framework of the AR regulatory pathway for all subsets of the population, projects are
supported by two service cores (Core A- Administrative, Core B- Multispecies Efficacy and Pharmacometric
Modeling Core) and two consortium cores (Coordinating Center Core, and the Opportunities Fund
Management Core). Core B offers one of, if not the most, comprehensive animal model platforms available for
MCM testing within the broader CMCR consortia, and includes rabbit, minipig, and non-human primate models
of ARS and/or DEARE.
INTERACT is synergistic with other potential Centers by offering capabilities and resources currently
unavailable to other sites through data and resource sharing and technology transfer to advance and strengthen
the National Institute of Allergy and Infectious Diseases (NIAID)/National Institute of Health (NIH)’s mission to
ensure the nation’s preparedness to respond to a radiological or nuclear incident.
项目总结/摘要-总体
国际辐射对抗合作联盟(Inter-collaborative Radiation Countermeasures,简称INTERACT)成立于1999年,
目标是开发安全有效的医疗对策(MCM),以减轻和/或治疗急性,
在发生核爆炸时,
放射性或核(RadNuc)公共卫生紧急情况。多器官损伤的生物学复杂性
(MOI)与急性放射病(ARS)和急性辐射照射的延迟效应相关的失败
(DEARE)需要一种全面的、多学科的方法来有效地识别治疗的新靶点。
干预,并将有前途的MCM从研究实验室转移到先进的制药
根据美国食品药品监督管理局(FDA)的动物规则(AR)法规进行开发和批准
通路INTERACT是一个新成立的马里兰州医学院(UMSOM)中心,
医学辐射对策(CMCR)是国际公认的研究人员的合作伙伴关系
四个美国-在MCM开发方面拥有广泛专业知识的大学,一套独特的
动物模型平台,以及分享想法和质量实践的共同目标,
科学发现和MCMs的转化发展。
INTERACT项目广泛围绕一个共同的主题设计,通过以下方式促进组织再生:
靶向参与细胞变性的生物学过程,这些细胞变性有助于临床表现,
ARS/DEARE后迅速暴露于高剂量的全身照射(TBI)。候选MCM
研究目标是与辐射诱导加速老化过程相关的关键生物学机制
包括基因组不稳定性、线粒体损伤、细胞衰老和炎症,
ARS的造血(项目1)和胃肠道亚综合征(项目2,3),皮肤辐射损伤
(项目3)和DEARE(项目1和4)。调查中的每种MCM的初步数据
项目1-4已经显示出在施用后至少24小时的存活率的显著改善。
在临床前试验和某些临床试验中,推进MCM
在所有人群亚群的AR调节途径框架内开发,项目包括
由两个服务核心(核心A-管理,核心B-多物种功效和药理学)提供支持
建模核心)和两个联盟核心(协调中心核心和机会基金
管理核心)。核心B提供了一个,如果不是最全面的动物模型平台,可用于
在更广泛的CMCR联盟内进行MCM试验,包括兔、小型猪和非人灵长类动物模型
的ARS和/或DEARE。
INTERACT目前通过提供能力和资源,与其他潜在的中心协同增效。
通过数据和资源共享以及技术转让,
国家过敏和传染病研究所(NIAID)/国家卫生研究所(NIH)的使命是
确保国家做好应对放射性或核事故的准备。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
France Carrier其他文献
France Carrier的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('France Carrier', 18)}}的其他基金
Preclinical Evaluation of Radioprotectin-1 for Mitigation of GI-ARS
Radioprotectin-1 缓解 GI-ARS 的临床前评估
- 批准号:
10770849 - 财政年份:2023
- 资助金额:
$ 243.81万 - 项目类别:
Intercollaborative Radiation Countermeasure (INTERACT) Consortium for Advanced Development of Medical Countermeasures to Mitigate/Treat Acute and Delayed Radiation Syndromes
相互协作辐射对策 (INTERACT) 联盟,促进减轻/治疗急性和迟发性辐射综合症的医疗对策高级发展
- 批准号:
10665553 - 财政年份:2020
- 资助金额:
$ 243.81万 - 项目类别:
Chemopotentiation by Low Dose Fractionated Radiation Therapy for disseminated intra-abdominal cancers
低剂量分割放射治疗播散性腹腔内癌症的化学增强作用
- 批准号:
9349730 - 财政年份:2017
- 资助金额:
$ 243.81万 - 项目类别:
Chemopotentiation by Low Dose Fractionated Radiation Therapy for disseminated intra-abdominal cancers
低剂量分割放射治疗播散性腹腔内癌症的化学增强作用
- 批准号:
10327267 - 财政年份:2017
- 资助金额:
$ 243.81万 - 项目类别:
Rational targeting of protein translation of cancer treatments
癌症治疗的蛋白质翻译的合理靶向
- 批准号:
8866371 - 财政年份:2013
- 资助金额:
$ 243.81万 - 项目类别:
Rational targeting of protein translation of cancer treatments
癌症治疗的蛋白质翻译的合理靶向
- 批准号:
9089875 - 财政年份:2013
- 资助金额:
$ 243.81万 - 项目类别:
Rational targeting of protein translation of cancer treatments
癌症治疗的蛋白质翻译的合理靶向
- 批准号:
8560772 - 财政年份:2013
- 资助金额:
$ 243.81万 - 项目类别:
Rational targeting of protein translation of cancer treatments
癌症治疗的蛋白质翻译的合理靶向
- 批准号:
8688187 - 财政年份:2013
- 资助金额:
$ 243.81万 - 项目类别:
Biomodulation of anticancer drugs targeting DNA
靶向DNA的抗癌药物的生物调节
- 批准号:
7619892 - 财政年份:2007
- 资助金额:
$ 243.81万 - 项目类别:
Biomodulation of anticancer drugs targeting DNA
靶向DNA的抗癌药物的生物调节
- 批准号:
7259571 - 财政年份:2007
- 资助金额:
$ 243.81万 - 项目类别:
相似海外基金
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 243.81万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The impact of changes in social determinants of health on adolescent and young adult mental health during the COVID-19 pandemic: A longitudinal study of the Asenze cohort in South Africa
COVID-19 大流行期间健康社会决定因素的变化对青少年和年轻人心理健康的影响:南非 Asenze 队列的纵向研究
- 批准号:
10755168 - 财政年份:2023
- 资助金额:
$ 243.81万 - 项目类别:
A Priority Setting Partnership to Establish a Patient, Caregiver, and Clinician-identified Research Agenda for Adolescent and Young Adult Cancer in Canada
建立优先合作伙伴关系,以建立患者、护理人员和临床医生确定的加拿大青少年和年轻人癌症研究议程
- 批准号:
480840 - 财政年份:2023
- 资助金额:
$ 243.81万 - 项目类别:
Miscellaneous Programs
Incidence and Time on Onset of Cardiovascular Risk Factors and Cardiovascular Disease in Adult Survivors of Adolescent and Young Adult Cancer and Association with Exercise
青少年和青年癌症成年幸存者心血管危险因素和心血管疾病的发病率和时间以及与运动的关系
- 批准号:
10678157 - 财政年份:2023
- 资助金额:
$ 243.81万 - 项目类别:
Fertility experiences among ethnically diverse adolescent and young adult cancer survivors: A population-based study
不同种族青少年和年轻成年癌症幸存者的生育经历:一项基于人群的研究
- 批准号:
10744412 - 财政年份:2023
- 资助金额:
$ 243.81万 - 项目类别:
Treatment development for refractory leukemia using childhood/adolescent, and young adult leukemia biobank
利用儿童/青少年和青年白血病生物库开发难治性白血病的治疗方法
- 批准号:
23K07305 - 财政年份:2023
- 资助金额:
$ 243.81万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular design of Two-Way Player CAR-T cells to overcome disease/antigen heterogeneity of childhood, adolescent, and young adult cancers
双向 CAR-T 细胞的分子设计,以克服儿童、青少年和年轻成人癌症的疾病/抗原异质性
- 批准号:
23H02874 - 财政年份:2023
- 资助金额:
$ 243.81万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Effects of adolescent social isolation on adult decision making and corticostriatal circuitry
青少年社会隔离对成人决策和皮质纹状体回路的影响
- 批准号:
10756652 - 财政年份:2023
- 资助金额:
$ 243.81万 - 项目类别:
Adolescent trauma produces enduring disruptions in sleep architecture that lead to increased risk for adult mental illness
青少年创伤会对睡眠结构产生持久的破坏,从而导致成人精神疾病的风险增加
- 批准号:
10730872 - 财政年份:2023
- 资助金额:
$ 243.81万 - 项目类别:
Using Tailored mHealth Strategies to Promote Weight Management among Adolescent and Young Adult Cancer Survivors
使用量身定制的移动健康策略促进青少年和年轻癌症幸存者的体重管理
- 批准号:
10650648 - 财政年份:2023
- 资助金额:
$ 243.81万 - 项目类别: